Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
A0PK11
UPID:
CLRN2_HUMAN
Alternative names:
-
Alternative UPACC:
A0PK11
Background:
Clarin-2, encoded by the gene with accession number A0PK11, is pivotal in auditory processes. It is essential for the normal organization and maintenance of the stereocilia bundle, crucial for hearing. This protein's role in mechano-electrical transduction underlines its importance in the auditory system.
Therapeutic significance:
Clarin-2's involvement in autosomal recessive deafness, specifically Deafness, autosomal recessive, 117, highlights its potential as a therapeutic target. Understanding the role of Clarin-2 could open doors to novel therapeutic strategies for sensorineural hearing loss.